Interventions for improving bone mineral density and reducing fracture risk in osteogenesis imperfecta: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials.

CONCLUSION: Oral bisphosphonates and teriparatide significantly increase BMD but are not associated with fracture risk reduction. Of the available interventions, oral bisphosphonates could perform better than others in osteogenesis imperfecta. This evidence should be considered preliminary and may change with future head-to-head clinical trials. PMID: 30160216 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research